243 related articles for article (PubMed ID: 25945045)
1. Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.
Asai K; Kobayashi A; Makihara Y; Johnson M
Int J Chron Obstruct Pulmon Dis; 2015; 10():803-11. PubMed ID: 25945045
[TBL] [Abstract][Full Text] [Related]
2. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
[TBL] [Abstract][Full Text] [Related]
3. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
4. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
[TBL] [Abstract][Full Text] [Related]
5. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
6. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
[TBL] [Abstract][Full Text] [Related]
8. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
9. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
Vogelmeier CF; Chapman KR; Miravitlles M; Roche N; Vestbo J; Thach C; Banerji D; Fogel R; Patalano F; Olsson P; Kostikas K; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1125-1134. PubMed ID: 29692607
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
12. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
[TBL] [Abstract][Full Text] [Related]
13. Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.
Gao J; Pleasants RA
Int J Chron Obstruct Pulmon Dis; 2015; 10():775-89. PubMed ID: 25926729
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
Płoszczuk A; Bosheva M; Spooner K; McIver T; Dissanayake S
Ther Adv Respir Dis; 2018; 12():1753466618777924. PubMed ID: 29857783
[TBL] [Abstract][Full Text] [Related]
16. Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD.
Yang L; Ma QL; Yao W; Zhang Q; Chen HP; Wang GS; Wang CZ
Respir Res; 2011 Oct; 12(1):142. PubMed ID: 22032685
[TBL] [Abstract][Full Text] [Related]
17. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
Kew KM; Seniukovich A
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010115. PubMed ID: 24615270
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
19. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Beeh KM; Kirsten AM; Tanase AM; Richard A; Cao W; Hederer B; Beier J; Kornmann O; van Zyl-Smit RN
Int J Chron Obstruct Pulmon Dis; 2018; 13():3923-3936. PubMed ID: 30584293
[TBL] [Abstract][Full Text] [Related]
20. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK;
Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]